PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Dig Dis Sci. Author manuscript; available in PMC 2010 November 1.
Published in final edited form as:
Dig Dis Sci. 1993 August; 38(8): 1489–1491.
PMCID: PMC2967386
NIHMSID: NIHMS242451

Lack of Association Between HLA Antigen DR3 and α1-Antitrypsin Deficiency in Liver Transplant Recipients

Abstract

The relationship between α1-antitrypsin deficiency (α1-ATD) and the HLA antigen system was studied in 32 liver transplant recipients. Despite previous reports of an association of HLA antigen DR3 with homozygosity for α1-AT ZZ, no such association was seen in this population of α1ATD homozygous ZZ patients with advanced hepatic disease. Thus, the reported association of HLA class II antigens and homozygosity for the Z allele for α1-AT may be an artifact of either a small study population or geographic inbreeding and a coincidental association of certain HLA antigens with the presence of homozygosity for the Z allele of α1-AT.

Keywords: HLA antigen, α1-antitrypsin, liver transplant

Liver transplantation is a life-saving therapy for individuals with end-stage liver disease for whom medical therapy does not exist (17). These individuals by definition represent the worse cases. Should an association between the presence of a given liver disease and certain HLA antigens exist, such an association would be expected to be readily demonstrable in individuals with the most severe disease, such as those requiring liver transplantation. The demonstration of such an association in liver transplant recipients with a given disease would be expected to occur as a result of a selection bias in which the more severely diseased cases are identified and selectively referred for transplantation. Therefore, in order to either confirm or refute the reported association between HLA antigen DR3 with α1-ATD (homozygosity for the Z allele). the following study was performed.

MATERIALS AND METHODS

Between January 1, 1980, and December 31, 1990, a total of 2500 liver transplants were performed at the University of Pittsburgh Medical Center (UPMC). Of these, 1888 were adult cases and 612 were pediatric cases. During this time, 47 patients with α1-ATD homozygous ZZ were seen and transplanted. Of this group, 32 (68%) underwent HLA typing prior to their transplant and were utilized for the analysis that follows: 18 were male and 14 were female. Their ages ranged from 10 months to 57 years (mean 15.65 ± 14.6).

In each case, the diagnosis of α1-ATD was confirmed by quantitation of the serum α1-AT level and determination of the Pi phenotype and as a result of family studies(810).

α1-Antitrypsin Studies

For the quantitative assay, serum levels of α-1-AT were quantitated by rate nephelometry using the Beckman Array Protein System (8, 9). Normal levels at UPMC are 85–213 mg/dl. Determination of the α1-AT Pi phenotype was performed using isoelectric focusing on agarose gel (10). Standards were utilized in each run. For family studies, whenever possible the patients’ siblings, parents, and children were studied to confirm the α1-AT phenotype.

HLA Typing

HLA typing was performed using lymphocytes isolated from the peripheral blood of each individual utilizing a standard NIH microlymphocytotoxicity assay and an immunomagnetic fluorescence technique for the DR typing (11, 12)

Liver Histology

The pathological findings of the resected livers were characterized grossly and by a histologic examination performed by staff pathologists at Presbyterian University and Children’s Hospital of Pittsburgh. The records of these examinations were reviewed.

Statistical Analysis

All values are reported as mean ± SEM. Statistical analyses were performed utilizing chis-quare analysis; P < 0.05 was considered significant.

RESULTS

Twenty-one children having a mean age of 6.8 ± 3.6 years and 11 adults having a mean age of 32.5 ± 12.8 years with α1-ATD and ZZ phenotype were studied. They represent 0.3% of the children and 0.6% of the adults transplanted at the University of Pittsburgh Medical Center during the 10-year period of this study.

HLA Antigens

The prevalence of HLA antigen DR3 in a control group of 200 normal blood donors in Pittsburgh was 22.6%. The prevalence of this antigen in the 32 patients studied as part of this investigation is shown in Table 1. Whether one looks at the cases in adults, children, or all of the cases transplanted for α1-ATD, a reduced prevalence of DR3 was found as compared to a normal control population. None of these differences are significant.

Table 1
Prevalence of HLA Antigen DR3 in Patients Coming to OLTx for α1-Antitrypsin Deficiency (P1 ZZ Phenotype)

α1-Antitrypsin Levels

The serum α1-AT level of these 32 patients as well as those of a group of liver disease controls consisting of 22 adults and 44 children matched for age (two for each case with α1-ATD) also transplanted at the University of Pittsburgh Medical Center during the study period is shown in Table 2. As expected, the patients with α1-ATD had very low levels of the protease inhibitor in their sera prior to OLTx. In contrast, compared to normal controls, the non-α1-ATD cases coming to OLTx had increased serum levels of α1-AT

TABLE 2
α1-Antitrypsin Levels (Mean Values) at Time Of OLTx

Liver Histology

The histological findings of the 32 cases studied are reported in Table 3. Of interest is the fact that no case of α1-AT was found to have a cholangiocarcinoma and only one pediatric patient was found to have a hepatoma. These figures stand in contrast to the 2% incidence of hepatocellular carcinoma in adults transplanted for hepatocellular disease other than α1-ATD and the 0.75% rate for all other children coming to OLTx.

TABLE 3
Frequency of hepatic cancer in 32 cases studied compared to that occurring in other types of Cirrhosis

DISCUSSION

In a study performed by Doherty et al (13), it was reported that DR3 occurs more frequently in patients with α1-ATD having a liver disease, suggesting that in these patients this allele may influence the outcome of the liver disease seen as part of the greater spectrum of α1-ATD disease.

Doubts about such an association in individuals with α1-ATD arose when other groups such as those of Nemeth and Möller (14) could not confirm the association of this allele with development of liver disease in children with α1-ATD.

To resolve this controversy, the present study was initiated. Because of the relative rarity of homozygous ZZ α1-ATD as a cause of clinical liver disease and because of the large number of HLA antigens that are recognized to exist currently, the present study was biased in favor of finding an association by examining only the HLA antigen present in individuals with α1-ATD coming to OLTx. Specifically, we selected the poorer cases for study. Were an association between certain HLA antigens and α1-ATD liver disease to exist, one would have expected an enrichment of these HLA antigens in a population of individuals with liver disease sufficiently severe as to be referred for liver transplantation. Such would appear to be the case for other liver disease like autoimmune chronic active hepatitis, sclerosing cholangitis, and chronic HBV-related liver disease (1519). Despite this bias in the accrual of subjects for this study, no association between any HLA antigens and particularly DR3 was found in either children or adults or both groups combined having α1-ATD liver disease confirmed by quantitation of the serum α1-AT level, isoelectric focusing for phenotype analysis, and family studies of the probands as well as having a need for OLTx. Therefore, based upon this biased, worst-case population, no association between HLA antigen DR3 and α1-ATD liver disease appears to exist.

Acknowledgments

Aided by Research Grants from the Veterans Administration and Project Grant DK29961 from the National Institutes of Health. Bethesda. Maryland.

References

1. Starzl TE, Demetris AJ, Van Thiel DH. Medical progress: Liver transplantation. Part I and II. N Engl J Med. 1989;221:600–603. 1014–1022.
2. Hood JM, Koep LJ, Peters RL, Schröter GP, Weil R, Redeker AG, Starzl TE. Liver transplantation for advanced liver disease with alpha-1-antitrypsin deficiency. N Engl J Med. 1980;302:272–275. [PMC free article] [PubMed]
3. Sharp HL, Bridges RA, Krivit W, Freier EF. Cirrhosis associated with alpha-1-antitrypsin deficiency: A previously unrecognized inherited disorder. J Lab Clin Med. 1969;73:934–939. [PubMed]
4. Sveger T. Liver disease in alpha-1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med. 1976;294:1316–1321. [PubMed]
5. Hodges JR, Millward-Sadler GH, Barbatis C, Wright R. Heterozygous MZ alpha-1-antitrypsin deficiency in adults with chronic active hepatitis and cryptogenic cirrhosis. N Engl J Med. 1978;304:557–560. [PubMed]
6. Alpha-1-antitrypsin deficiency and liver disease. Br Med J. 1981;283:807–808. [PMC free article] [PubMed]
7. Cox DW, Smith S. Risk for liver disease in adults with alpha-1-antitrypsin deficiency. Am J Med. 1983;74:221–227. [PubMed]
8. Sternberg JC. A rate nephelometer for measuring specific proteins by immunoprecipitin reactions. Clin Chem. 1977;23:1456. [PubMed]
9. Killingsworth LM, Savory J. Nephelometric studies of the precipitin reaction: A model system for specific protein measurements. Clin Chem. 1973;19:403. [PubMed]
10. Saravis CA. Electrophoresis ‘81: Agarose isoelectric focusing workshop. FMC Corporation; Charleston, South Carolina: Apr 6, 1981.
11. Zachary AA, Theresi GA, editors. ASHI Laboratory Manual. 2. American Society for Histocompatibility and Immunogenetics; Lenexa, Kansas: 1990.
12. McQueen JM, editor. SEOPF Tissue Typing Reference Manual SEOPF. Richmond, Virginia: 1987.
13. Doherty DG, Donaldson PT, Whitehouse DB, Mieli-Vergani G, Duthie A, Hopkinson DA, Mowat AP. HLA phenotypes and gene polymorph isms in juvenile liver disease associated with α1antitrypsin deficiency. Hepatology. 1990;12:218–223. [PubMed]
14. Nemeth A, Möller E. HLA in juvenile liver disease with alpha-one-antitrypsin deficiency. Acta Pediatr Scand. 1987;76:603–607. [PubMed]
15. Opelz G, Vogten AJM, Summerskill WHJ, Schalm SW, Terasaki PI. HLA determinants in chronic active liver disease: Possible relation of HLA-Dw3 to prognosis. Tissue Antigens. 1977;9:36–40. [PubMed]
16. MacKay IR, Tait BD. HLA associations with autoimmune-type chronic active hepatitis: Identification of the B8-DRw3 haplotype by family studies. Gastroenterology. 1980;79:95–98. [PubMed]
17. Chapman RW, Varghese Z, Gaul R, Patel G, Kokinon N, Sherlock S. Association of primary sclerosing cholangitis with HLA-B8. Gut. 1983;24:38–41. [PMC free article] [PubMed]
18. Forzani B, Actis GC, Verne G. HLA-DR antigens in HB-sAg-positive chronic active liver disease with and without associated delta infection. Hepalology. 1984;4:1107–1110. [PubMed]
19. Nouri-Aria KT, Donaldson PT, Hegarty JE, Eddleston ALWF, Williams R. HLA A1-B8-DR3 and suppressor cell function in first-degree relatives of patients with autoimmune chronic active hepatitis. J Hepatol. 1985;35:235–241. [PubMed]
20. Tait B, Mackay IR, Board P, Coggan M, Emery P, Echardt G. HLA A1. B8, DR3 extended halotypes in autoimmune chronic hepatitis. Gastroenterology. 1989;97:479481. [PubMed]